John Siedlecki, MD
Family Medicine · Midlothian, VANPI 1316986664
Payments from drug & device makers
Across 172 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$525
- Novo Nordisk$453
- AstraZeneca$239
- Lilly USA, LLC$191
- Pfizer$173
- Amarin Pharma, Inc.$169
- plus $935 from 27 others
What the payments were for
- Food & beverage$2,67199%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $525 |
| Novo Nordisk | 29 | $453 |
| AstraZeneca | 17 | $239 |
| Lilly USA, LLC | 10 | $191 |
| Pfizer | 11 | $173 |
| Amarin Pharma, Inc. | 13 | $169 |
| Amgen | 9 | $137 |
| Actelion Pharmaceuticals US, Inc. | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $92 |
| GSK | 5 | $77 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Boston Scientific | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Merck | 2 | $28 |
| Concordia Pharmaceuticals Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Shire North American Group Inc | 2 | $25 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Johnson & Johnson | 2 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Biogen | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$2,685 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $104,035 |
| EliquisApixaban | 63 | $90,651 |
| JanuviaSitagliptin Phosphate | 28 | $32,039 |
| FarxigaDapagliflozin Propanediol | 20 | $31,268 |
| TrulicityDulaglutide | 33 | $29,874 |
| JardianceEmpagliflozin | 17 | $25,673 |
| XareltoRivaroxaban | 19 | $24,862 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $19,060 |
| MounjaroTirzepatide | 13 | $17,726 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,230 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $10,085 |
| SynthroidLevothyroxine Sodium | 94 | $7,308 |
| MyrbetriqMirabegron | 13 | $6,937 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,011 |
| DuleraMometasone/Formoterol | 14 | $5,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $453 | $104,03557 claims |
| PfizerEliquis, Paxlovid | $173 | $93,510106 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $191 | $47,60046 claims |
| AstraZenecaFarxiga, Symbicort | $239 | $41,35245 claims |
| MerckJanuvia, Dulera | $28 | $37,55742 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $77 | $29,92749 claims |
| Boehringer IngelheimJardiance | $22 | $25,67317 claims |
| Johnson & JohnsonXarelto | $23 | $24,86219 claims |
| AbbVieSynthroid | $525 | $7,30894 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Midlothian
- Aaron HartmanMidlothian$17.4M
- Jennifer BrownMidlothian$1.3M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.